An Observational Study Assessing the Long-term Risk of Non-Melanoma Skin Cancer (NMSC) Among New Users of OpzeluraTM (Ruxolitinib) Cream in a Vitiligo Patient Population: Post-Authorization Safety Study (PASS)

20/01/2025
21/05/2025
EU PAS number:
EUPAS1000000413
Study
Planned
Documents
Study protocol
Study results
Study report
Other information